(CYTK) Cytokinetics - Ratings and Ratios
Omecamtiv, Aficamten, CK089, CK586
CYTK EPS (Earnings per Share)
CYTK Revenue
Description: CYTK Cytokinetics
Cytokinetics Inc (NASDAQ: CYTK) is a late-stage biopharmaceutical company focused on developing innovative treatments for debilitating diseases, primarily in the United States. The companys pipeline includes several promising candidates, such as omecamtiv mecarbil, a cardiac myosin activator in Phase III clinical trials for heart failure, and aficamten, a cardiac myosin inhibitor in Phase III clinical trials for hypertrophic cardiomyopathy.
From a business perspective, Cytokinetics has established strategic partnerships, including a collaboration with Ji Xing Pharmaceuticals Limited and a license agreement for the development and commercialization of aficamten in Japan. These partnerships can potentially expand the companys global reach and revenue streams. Key performance indicators (KPIs) to monitor include the progress of their clinical trials, partnership milestones, and the companys cash burn rate, which is crucial for a biotech company with significant R&D expenses.
In terms of financials, Cytokinetics has a market capitalization of approximately $4.64 billion. The absence of a P/E ratio is not surprising given the companys focus on R&D and lack of profitability. Return on Equity (RoE) stands at 801.26%, indicating a significant return on shareholders equity, although this metric should be interpreted with caution in the context of a company with negative earnings. Other KPIs to watch include the companys cash reserves, total debt, and research and development expenses as a percentage of revenue.
From a growth perspective, the success of Cytokinetics drug candidates in clinical trials is crucial. The progression of omecamtiv mecarbil and aficamten through Phase III trials is particularly important, as it could lead to FDA approval and commercialization. The companys ability to execute on its clinical development plans, secure regulatory approvals, and effectively commercialize its products will be key drivers of future growth. Investors should closely monitor updates on clinical trial results, regulatory milestones, and partnership announcements.
CYTK Stock Overview
| Market Cap in USD | 5,982m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2004-04-29 |
CYTK Stock Ratings
| Growth Rating | -17.9% |
| Fundamental | 44.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -23.8% |
| Analyst Rating | 4.29 of 5 |
CYTK Dividends
Currently no dividends paidCYTK Growth Ratios
| Growth Correlation 3m | 75.3% |
| Growth Correlation 12m | -77.3% |
| Growth Correlation 5y | 60.1% |
| CAGR 5y | -2.13% |
| CAGR/Max DD 3y | -0.03 |
| CAGR/Mean DD 3y | -0.05 |
| Sharpe Ratio 12m | -0.44 |
| Alpha | -23.99 |
| Beta | 0.832 |
| Volatility | 66.00% |
| Current Volume | 1896.6k |
| Average Volume 20d | 1975.6k |
| Stop Loss | 48.3 (-5.5%) |
| Signal | -1.18 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-606.3m TTM) > 0 and > 6% of Revenue (6% = 5.14m TTM) |
| FCFTA -0.33 (>2.0%) and ΔFCFTA -5.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 881.1% (prev 30.8k%; Δ -29.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.35 (>3.0%) and CFO -426.9m > Net Income -606.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (119.5m) change vs 12m ago 9.35% (target <= -2.0% for YES) |
| Gross Margin -227.0% (prev -2887 %; Δ 2660 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 6.24% (prev 0.21%; Δ 6.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.58 (EBITDA TTM -504.8m / Interest Expense TTM 92.1m) >= 6 (WARN >= 3) |
Altman Z'' -8.42
| (A) 0.62 = (Total Current Assets 886.5m - Total Current Liabilities 131.1m) / Total Assets 1.23b |
| (B) -2.45 = Retained Earnings (Balance) -3.00b / Total Assets 1.23b |
| warn (B) unusual magnitude: -2.45 — check mapping/units |
| (C) -0.37 = EBIT TTM -514.2m / Avg Total Assets 1.37b |
| (D) -1.88 = Book Value of Equity -3.00b / Total Liabilities 1.59b |
| Total Rating: -8.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.80
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.81% = -3.41 |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -1.48 = -2.50 |
| 7. RoE data missing |
| 8. Rev. Trend 29.94% = 1.50 |
| 9. Rev. CAGR 229.5% = 2.50 |
| 10. EPS Trend 68.16% = 1.70 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CYTK shares?
Over the past week, the price has changed by -1.84%, over one month by +32.05%, over three months by +51.36% and over the past year by -9.90%.
Is Cytokinetics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CYTK is around 44.74 USD . This means that CYTK is currently overvalued and has a potential downside of -12.5%.
Is CYTK a buy, sell or hold?
- Strong Buy: 9
- Buy: 9
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CYTK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.5 | 45.8% |
| Analysts Target Price | 74.5 | 45.8% |
| ValueRay Target Price | 49.8 | -2.5% |
Last update: 2025-09-05 04:38
CYTK Fundamental Data Overview
CCE Cash And Equivalents = 858.1m USD (Cash And Short Term Investments, last quarter)
P/S = 69.7667
P/B = 60.3093
P/EG = -0.42
Beta = 0.648
Revenue TTM = 85.7m USD
EBIT TTM = -514.2m USD
EBITDA TTM = -504.8m USD
Long Term Debt = 713.0m USD (from longTermDebt, last quarter)
Short Term Debt = 34.0m USD (from shortTermDebt, last quarter)
Debt = 747.0m USD (Calculated: Short Term 34.0m + Long Term 713.0m)
Net Debt = 624.1m USD (from netDebt column, last quarter)
Enterprise Value = 5.87b USD (5.98b + Debt 747.0m - CCE 858.1m)
Interest Coverage Ratio = -5.58 (Ebit TTM -514.2m / Interest Expense TTM 92.1m)
FCF Yield = -6.81% (FCF TTM -399.8m / Enterprise Value 5.87b)
FCF Margin = -466.3% (FCF TTM -399.8m / Revenue TTM 85.7m)
Net Margin = -707.2% (Net Income TTM -606.3m / Revenue TTM 85.7m)
Gross Margin = -227.0% ((Revenue TTM 85.7m - Cost of Revenue TTM 280.4m) / Revenue TTM)
Tobins Q-Ratio = -1.96 (set to none) (Enterprise Value 5.87b / Book Value Of Equity -3.00b)
Interest Expense / Debt = 3.25% (Interest Expense 24.3m / Debt 747.0m)
Taxrate = 21.0% (US default)
NOPAT = -514.2m (EBIT -514.2m, no tax applied on loss)
Current Ratio = 6.76 (Total Current Assets 886.5m / Total Current Liabilities 131.1m)
Debt / EBITDA = -1.48 (Net Debt 624.1m / EBITDA -504.8m)
Debt / FCF = -1.87 (Debt 747.0m / FCF TTM -399.8m)
Total Stockholder Equity = -196.1m (last 4 quarters mean)
RoA = -49.47% (Net Income -606.3m, Total Assets 1.23b )
RoE = unknown (Net Income TTM -606.3m / Total Stockholder Equity -196.1m)
RoCE = -99.47% (set to none) (Ebit -514.2m / (Equity -196.1m + L.T.Debt 713.0m))
RoIC = -107.4% (set to none) (NOPAT -514.2m / Invested Capital 478.6m)
WACC = 8.36% (E(5.98b)/V(6.73b) * Re(9.08%)) + (D(747.0m)/V(6.73b) * Rd(3.25%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.23%
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -399.8m)
Revenue Correlation: 29.94 | Revenue CAGR: 229.5%
Rev Growth-of-Growth: 183.3
EPS Correlation: 68.16 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -5.82
Additional Sources for CYTK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle